Hyaluronan coating improves liver engraftment of transplanted human biliary tree stem/progenitor cells
- Lorenzo Nevi†1,
- Guido Carpino†2,
- Daniele Costantini1,
- Vincenzo Cardinale1,
- Olga Riccioni3,
- Sabina Di Matteo1,
- Fabio Melandro4,
- Pasquale Bartolomeo Berloco4,
- Lola Reid5,
- Eugenio Gaudio3, 8Email author and
- Domenico Alvaro6, 7Email author
© The Author(s). 2017
Received: 27 August 2016
Accepted: 28 January 2017
Published: 20 March 2017
Cell therapy of liver diseases with human biliary tree stem cells (hBTSCs) is biased by low engraftment efficiency. Coating the hBTSCs with hyaluronans (HAs), the primary constituents of all stem cell niches, could facilitate cell survival, proliferation, and, specifically, liver engraftment given that HAs are cleared selectively by the liver.
We developed a fast and easy method to coat hBTSCs with HA and assessed the effects of HA-coating on cell properties in vitro and in vivo.
The HA coating markedly improved the viability, colony formation, and population doubling of hBTSCs in primary cultures, and resulted in a higher expression of integrins that mediate cell attachment to matrix components. When HA-coated hBTSCs were transplanted via the spleen into the liver of immunocompromised mice, the engraftment efficiency increased to 11% with respect to 3% of uncoated cells. Notably, HA-coated hBTSC transplantation in mice resulted in a 10-fold increase of human albumin gene expression in the liver and in a 2-fold increase of human albumin serum levels with respect to uncoated cells. Studies in distant organs showed minimal ectopic cell distribution without differences between HA-coated and uncoated hBTSCs and, specifically, cell seeding in the kidney was excluded.
A ready and economical procedure of HA cell coating greatly enhanced the liver engraftment of transplanted hBTSCs and improved their differentiation toward mature hepatocytes. HA coating could improve outcomes of stem cell therapies of liver diseases and could be immediately translated into the clinic given that GMP-grade HAs are already available for clinical use.
KeywordsAdult stem cells Cell transplantation Hepatocyte differentiation Hyaluronan Liver
Liver transplantation is the only therapeutic option for many congenital and acquired liver diseases [1–3]. However, the requirements of this procedure and the paucity of organs available for transplantation limit this option to a minority of patients [1–3]. Cell therapy is a promising treatment strategy [1, 2, 4] and in this regard different cell sources have been tested, including hepatic stem cells (HpSCs), biliary tree stem cells (BTSCs), mesenchymal stem cells, adipose-derived stem cells, umbilical cord cells, amniotic fluid-derived epithelial cells, embryonic stem cells (ESCs), and induced pluripotent stem (iPS) cells [1, 2].
Recently, we successfully transplanted patients with advanced cirrhosis by infusing human biliary tree stem cells (hBTSCs) into the hepatic artery . However, the homing and the liver engraftment of administered cells remain a key issue. Transplantation of such stem cell populations via the portal vein results in less than 5% engraftment [3, 5, 6]. Direct injection into the liver parenchyma results in ~10–20% engraftment . The highest engraftment observed for transplantation of stem cells into the liver via a vascular route was reported by Khan et al.  who administered the cells via the hepatic artery. These findings were corroborated by others . In addition, transplantation by any vascular route, either portal vein, hepatic artery, or spleen, resulted in significant ectopic cell distribution to the vascular beds of all tissues assayed. Moreover, the cells survived for months, increasing the risk of ectopic liver formation with unknown clinical consequences . There is therefore a need for methods to increase localization of the transplanted cells to the target tissue.
Coinjection of human HpSCs with hyaluronans (HAs) triggered to form HA hydrogels into the livers of immunocompromised mice resulted in essentially 100% engraftment, an absence of ectopic cell distribution, and an extent of humanization of host livers at 2 weeks comparable with that at 3–5 months if transplanted without HA . The use of natural and synthetic scaffolds has been considered by many [3, 7, 9–12].
HAs are of especial interest for stem cell therapies. They are polymers of the glucuronic acid–N-acetyl glucosamine dimer, are anionic, are nonsulfated, and are major constituents of all stem cell niches. HAs can be prepared as liquids that can be converted into hydrogels with remarkable chemical and mechanical properties ideal for cell populations, having perfect elasticity and enabling interstitial fluids complete access throughout the gel . In addition, diverse forms of HA receptors, CD44 isoforms, are generic biomarkers of all known stem cell populations . HAs, both in liquid and hydrogel forms, have been shown to promote stem cell survival and proliferation, to optimize spheroid/organoid formation of normal and transformed stem cells, and to optimize cryopreservability of stem cells [7, 11, 14–17]. They have also demonstrated promise in cell delivery [7, 18–21]. It is noteworthy that HA is renowned for fostering vascularization, and is readily modified by the cells as needed for integration into the tissue and with enzymes (e.g., hyaluronidases) and by hydrolysis native to the liver [7, 11, 18–21].
As a novel strategy to improve the liver engraftment of hBTSCs we are proposing to coat hBTSCs with HAs and to use them for cell therapy of liver diseases. We hypothesize that this strategy could be successful for the liver given that HA is selectively and specifically cleared by the liver [22, 23]. Moreover, HAs are largely used for different clinical applications, facilitating their use also in the setting of cell therapy . The main objectives of the present study were to evaluate the effect of HA coating: in vitro, on engraftment, proliferation, and differentiation of hBTSCs in primary cultures; and in vivo, on engraftment efficiency into the liver and differentiation toward mature hepatocytes of hBTSCs transplanted, via the spleen, into immune-compromised mice.
Human tissue sourcing
The cell source consisted of freshly isolated human biliary tree stem/progenitor cells (hBTSCs) obtained from the human extrahepatic biliary tree, comprising the common hepatic duct, bile duct, cystic duct, gallbladder, and hepato-pancreatic ampulla. Biliary tissues were obtained from organ donors because they were not used for transplantation at the “Paride Stefanini” Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy. Informed consent to use tissues for research purposes was obtained from our transplant program. All samples derived from adults between the ages of 19 and 73 years. Protocols received the approval of our Institutional Review Board, and processing was compliant with current Good Manufacturing Practice (cGMP). The research protocol was reviewed and approved by the Ethic Committee of Umberto I University Hospital, Rome, Italy. Freshly isolated hBTSCs have been characterized extensively in previous reports [24–26]. In the present report, the in-vitro experiments were performed by culturing primary freshly isolated cells, which were not passaged. Each set of experiments was performed on cells isolated from five different patients, in triplicate for each patient.
Tissue specimens were processed as described previously [7, 24, 25, 27, 28]. In brief, tissues were digested in RPMI 1640 supplemented with 0.1% human serum albumin, 1 nM selenium, antibiotics, type I collagenase (300 collagen digestion units/ml), 0.3 mg/ml deoxyribonuclease, at 37 °C with frequent agitation for 30–45 min.
Epithelial cell adhesion molecule sorting procedures
Cells were sorted for epithelial cell adhesion molecule (EpCAM) using magnetic beads as indicated by the manufacturer (MiltenyiBiotec Inc., Germany). Briefly, the EpCAM+ cells were magnetically labeled with EpCAM MicroBeads (catalog #130-061-101; MiltenyiBiotec Inc.) and loaded onto a MACS LS Column (catalog #130-042-401; MiltenyiBiotec Inc.) that was placed in the magnetic field of a MACS Separator. EpCAM+ cells were suspended in basal medium at a concentration of 300,000 cells/ml, and used as the final cell suspension. Sorted cells were characterized extensively by FACS analysis for EpCAM and many mesenchymal cell markers (CD45, CD31, CD34, CD90, α-SMA).
Media and solutions
All media were sterile filtered (0.22-μm filter) and kept in the dark at 4 °C before use. RPMI-1640, the basal medium used for all of the cell cultures, and fetal bovine serum (FBS) were obtained from GIBCO/Invitrogen (Carlsbad, CA, USA). All reagents were obtained from Sigma (St. Louis, MO, USA) unless otherwise specified.
Kubota’s Medium (KM) is a serum-free medium developed for survival and expansion of endodermal stem/progenitors  and subsequently shown to be successful with human HpSCs [30, 31], hBTSCs [24, 26, 28, 32], human pancreatic stem/progenitor cells , and rodent HpSCs . Mature endodermal cells do not survive in KM .The detailed protocol of its preparation was first reported by Kubota and Reid . Briefly, KM consists of any basal medium (here being RPMI 1640) with no copper, low calcium (0.3 mM), 10–9 M selenium, 4.5 mM nicotinamide, 0.1 nM zinc sulfate heptahydrate, 10–8 M hydrocortisone (or dexamethasone), 5 μg/ml transferrin/Fe, 5 μg/ml insulin, 10 μg/ml high-density lipoprotein, 0.1% human (or bovine) serum albumin (HSA or BSA), and a mixture of purified free fatty acids that are added bound to purified HSA. The medium is now available commercially through PhoenixSongs Biologicals (Branford, CT, USA).
Coating by hyaluronic acid
HA gel was made using HA powder (#S0780000; Sigma) dissolved in normal saline with a rate of 0.1% W/V and filtered by 0.22 μm. hBTSCs were counted by trypan blue, suspended with coating medium, mixed softly, and stored in an incubator for 10 min at 37 °C and 5.0 CO2. After 5 min in coating medium, hBTSCs were mixed softly.
Cell cultures and clonal expansion
EpCAM+ hBTSCs (approximately 3 × 105 cells), HA-coated or uncoated, were seeded onto 3-cm-diameter plastic culture dishes and kept overnight (~12 hours) in KM with 10% FBS. Thereafter cell cultures were maintained in serum-free KM. For testing the clonal expansion of hBTSCs, a single cell suspension was obtained, and the cells were plated on culture plastic at a clonal seeding density (500/cm2) . For in-vitro experiments, cells were cultured in serum-free KM (without passing).
Cell viability was determined by trypan blue exclusion assay (#302 643-25G; Sigma). The cells stained blue were dead; the viable cells did not stain. This dye was used at 1:1 v/v with the cell buffer. The cell count was carried out using FAST-READ 102 (#BSV100; Biosigma). Cells viability was calculated at four different time points: 1, 3, 7, and 14 days.
The hBTSC colonies began to appear after 1 day of plating and were easily identified by observing at 10× with a light microscope. Any size colony was counted as one, whether large ones at >3000 cells or small ones at <200 cells. Each well of the six well plates was evaluated using 10× magnification for colonies and counted during 2 weeks of culture. Microscopic fields were used as normalization. Observations of colony number, size, and morphology were noted.
The proliferation rate was analyzed on the same hBTSC population, seeded in six multiwell plates at a density of 1 × 104 cell/cm2, and cultured for 7 days. The cell counts were performed under two culture conditions: hBTSCs coated with HA; and hBTSCs uncoated.
The medium was changed every 3 days, using serum-free KM. The mean cell number was calculated on three experimental samples for each condition, and cell density was expressed as the mean of cells/cm2 ± standard deviation (SD). Cells were detached from supports and were counted by trypan blue assay; for these experiments we used only viable cells.
where N 7d is the cell number at day 7 and N 1d is the cell number at day 1.
where N is the harvested cell number and N s is the initial plated cell number.
Quantitative reverse-transcription polymerase chain reaction analysis
Total RNA was extracted by the procedures of Chomczynski and Sacchi . The expression of the genes was conducted by reverse-transcription and PCR amplification performed in a closed tube (OneStep RT-PCR; Qiagen, Hamburg, Germany) on total RNA samples extracted from cells and tissues. These genes were coamplified with the GAPDH housekeeping gene as a reference. The mRNA expression was measured by the quantification of amplicons with on-chip capillary microelectrophoresis performed with the Experion System (Bio-Rad, UK). The expression of the gene of interest was calculated by the ratio of the concentrations of the gene of interest and the reference gene GAPDH “in vitro” and β-actin “in vivo” (reported by the instrument in nmol/L) (Additional file 1: Table S1).
Immunofluorescence on cell cultures
For immunofluorescence (IF) on cell cultures, slide chambers were fixed in acetone for 10 min at room temperature and then rinsed with PBS-Tween 20. Nonspecific protein binding was blocked by 5% normal goat serum. Fixed cells were incubated with primary antibodies against HA (# BVN-3996 F-100; Vinci Biochem) and CD44 (# 3570; Cell Signaling Technology). Cells were then washed and incubated for 1 hour with labeled isotype-specific secondary antibodies (anti-mouse AlexaFluor-488, anti-rabbit AlexaFluor-594; Invitrogen, LifeTechnologies Ltd, Paisley, UK) and counterstained with 4,6′-diamidino-2-phenylindole (DAPI) for visualization of cell nuclei. For all immunoreactions, negative controls were also included and consisted of replacing the primary antibody with preimmune serum. Cultures were examined in a coded fashion by Leica Microsystems DM 4500 B Light and Fluorescence Microscopy (Weltzlar, Germany) equipped with a JenoptikProg Res C10 Plus Videocam (Jena, Germany). IF was also analyzed by confocal microscopy (Leica TCS-SP2) .
Cell transplantation in severely combined immunodeficient mice
All animal experiments were carried out in accordance with the EU Directive 2010/63/EU for animal experiments and with Sapienza institutional guidelines. The severely combined immunodeficient (SCID) mice (T/SOPF NOD.CB17 PRKDC/J) were male, 4-week-old animals and were used as the hosts for transplantation of human cells. Animals were sedated with an anesthetic drug (2, 2, 2-tribromoethanol). Thereafter, 2 × 106 hBTSCs coated with HA or uncoated (control cells) were suspended in 100 μl saline and injected into the liver via the spleen. Sham controls were infused only with 100 μl saline or with HA buffer 0.1% w/v. Then, 30 days after cell transplantation, mice were sacrificed and the livers removed for further analyses. Liver samples were placed in Trizol reagent for gene analyses or in 4% formalin for pathologic and immunohistochemistry (IHC) analyses. Blood samples were collected from the heart, centrifuged, and serum samples stored at –20 °C for quantification of human albumin by enzyme-linked immunosorbent assay (ELISA) (Albumin Human ELISA Kit, cat. N. ab108788; Abcam, Cambridge, UK).
Light microscopy and immunohistochemistry
Specimens were fixed in 10% buffered formalin for 2–4 hours, embedded in low-temperature-fusion paraffin (55–57 °C), and 3–4 μm sections were stained with hematoxylin–eosin and Sirius red/Fast green, according to standard protocols. For IHC, endogenous peroxidase activity was blocked by 30-min incubation in methanolic hydrogen peroxide (2.5%). Antigens were retrieved, as indicated by the vendor, by applying Proteinase K (code S3020; Dako, Glostrup, Denmark) for 10 min at room temperature. Sections were then incubated overnight at 4 °C with primary antibodies (Additional file 2: Table S2). Samples were rinsed twice with PBS for 5 min, incubated for 20 min at room temperature with secondary biotinylated antibody (LSAB+ System-HRP, code K0690; Dako) and then with Streptavidin-HRP (LSAB+ System-HRP, code K0690; Dako). Diaminobenzidine (Dako) was used as a substrate, and sections were counterstained with hematoxylin or with Periodic Acid–Schiff (PAS). For all immunoreactions, negative controls were included by replacing the primary antibody with preimmune serum. Sections were examined in a coded fashion by Leica Microsystems DM 4500 B Light and Fluorescence Microscopy (Weltzlar, Germany) equipped with a JenoptikProg Res C10 Plus Videocam (Jena, Germany). Observations were processed with an Image Analysis System (IAS; Delta Sistemi, Rome, Italy) and were independently performed by two pathologists in a blind fashion. A list of positive and negative controls is presented in Additional file 3: Table S3.
For IF, nonspecific protein binding was blocked with 5% normal goat serum. Sections were incubated with primary antibodies, and subsequently incubated with labeled isotype-specific secondary antibodies (anti-mouse AlexaFluor-488 and anti-rabbit Alexafluor-594; Invitrogen Ltd) for 1 hour; nuclei were visualized with DAPI . To perform double immunostaining with two mouse primary antibodies, we followed a three-step protocol: sections were incubated with the first primary antibody, an anti-mouse (or anti-rabbit) secondary fluorescent antibody (alexafluor-488) was applied, and the second primary antibody was prelabeled with a fluorophore using the APEX-594 labeling kit (Invitrogen) and applied to the section. All antibodies were diluted (1:50) and incubated for 1 hour. Slides were counterstained with DAPI. For all immunoreactions, adequate negative controls were also preformed .
All counts were performed in six nonoverlapping fields (magnification 20×) for each slide; at least three different slides were taken from each specimen. For IHC/IF staining, the number of positive cells was counted in a random, blinded fashion in six nonoverlapping fields (magnification 20×) for each slide/culture, and the data are expressed as % positive cells. The hBTSC engraftment in murine livers and their differentiation was assessed by IHC for anti-human antibodies (anti-human mitochondria) which do not react with mouse antigens, as described elsewhere .
Flow cytometry analysis
Isolated cells were labeled with fluorescent primary antibodies or adequate isotype controls. Cells were resuspended at approximately 2 × 105 cells/ml in PBS. Primary antibodies included EpCAM (EpCAM-FITC, catalog #130-080-301; MiltenyiBiotec Inc.), and many mesenchymal cell markers (CD45, CD31, CD34, CD90, α-SMA) (detailed information presented in Additional file 2: Table S2). Cells were analyzed by a BD FACScanto™ Flow Cytometer (Becton, Dickinson and Company, NJ, USA). Ten thousand events were acquired and analyzed by BD FACSDiva™ software (Becton, Dickinson and Company).
Data were expressed as mean ± SD. Statistical analyses were performed by SPSS statistical software (SPSS Inc., Chicago IL, USA). Differences between groups for nonnormal distribution parameters were tested by Mann–Whitney U tests. Statistical significance was set to p < 0.05.
Immediately after the isolation, hBTSCs were incubated with 0.1% HA (# S0780000; Sigma) in KM (0.1% weight/volume) and gently mixed for 10 min. The cells were then cultured in serum-free KM.
Colony formation is a well-established parameter of cell viability and attachment. Isolated HA-coated and uncoated hBTSCs were plated onto culture plastics and in KM at a density of 10,000 cells/ml, and after 3 days in culture the colonies were counted (Fig. 1b, c). A significantly higher number of cell colonies was present in HA-coated as compared with uncoated hBTSCs (uncoated hBTSCs: 6.93 ± 1.39; HA-coated hBTSCs: 15.07 ± 2.69; p < 0.001; N = 3) (Fig. 1b, c).
Effects of HA coating on hBTSC viability, proliferation, and gene expression in vitro
Engraftment of HA-coated (vs uncoated) hBTSCs after intrasplenic transplantation in mice
At same time point, human albumin gene expression in the liver was evaluated as a quantitative measure for stem cell engraftment and as a sign of differentiation toward mature human hepatocytes. Interestingly, before transplantation into the host, both HA-coated and uncoated freshly isolated hBTSCs showed minimal or null mRNA albumin levels with respect to hBTSCs cultured in high defined medium for hepatocyte differentiation (HDM-H) or with respect to primary mature hepatocytes (Additional file 4: Figure S1). Human albumin expression was analyzed by RT-qPCR utilizing human and mouse specific primer sequences. Data have been normalized with β-actin as a housekeeping gene. In the liver samples from mice transplanted with HA-coated hBTSCs, human albumin gene expression was markedly higher than in mice treated with uncoated hBTSCs (1.00 ± 0.84 vs 0.000008 ± 7.29; N = 3; p < 0.05; Fig. 5b). As a consequence, the human albumin/mouse albumin ratio (ALB homo/ALB mouse) resulted in markedly higher levels in mice treated with HA-coated than uncoated hBTSCs (0.39 ± 0.31 vs 0.000036 ± 0.000014; N = 3; p < 0.01). Circulating serum human albumin was measured by ELISA in transplanted mice after 4 weeks from transplantation. Mice treated with HA-coated hBTSCs showed a concentration of serum human albumin that was approximately double that found in mice transplanted with uncoated hBTSCs (117.62 ± 18.20 vs 64.94 ± 15 ng/dl; N = 3; p < 0.05; Fig. 5c). Human albumin was undetectable in sham operated control mice by the ELISA assay we used (n = 3; Fig. 5c).
Evaluation of ectopic distribution and seeding of transplanted cells
Coating of hBTSCs with hyaluronans (HA) resulted in significant improvement in engraftment of cells delivered by a vascular route to the liver. Many different strategies are currently under investigation to improve cell grafting, including the use of organic and inorganic biomatrices mimicking the microenvironment offered by the extracellular matrix [7, 37, 38]. HAs, major constituents of stem cell niches, are candidate coatings of stem cells used for cell therapies because they facilitate viability, proliferation, and engraftment in damaged livers. The chemical and mechanical properties of HA are conducive to essential requirements for stem cells. In addition, because the liver is a primary site for HA clearance, HA coating represents an advantageous strategy for the selective targeting of the transplanted cells to the liver. In our work, we tested the coating of hBTSCs with HA for its influence on engraftment into livers.
This molecule is already approved for Good Manufactory Practice (GMP) use and has been tested in clinical trials evaluating its effect on dental implant placement [39, 40], on treatment of arthritis after injections into joints , and for various types of cosmetic surgery .
A simple and rapid coating protocol was achieved and consisted of incubating cells in a 0.1% HA (weight/volume) solution for 10 min at room temperature. The IF analysis showed that HA was uniformly distributed around the whole cell surface, representing a homogeneous coating that was stable throughout the 2-week cultures. Previously, Roberts et al.  obtained similar findings but with polyethylene glycol (PEG).
A crucial issue in cell therapies is the size of transplanted cells. If the cells are large or if they form large aggregates, the transplantation of them via a vascular route can result in an embolus that can be life threatening. If the cells are small, their engraftment efficiency can be very low, and the cells will have a greater propensity to distribute to ectopic sites. Both possibilities are of importance for stem cell therapy considerations. Cells used for cell therapy of liver diseases have been infused into the liver via the spleen in animal models or into the portal vein or hepatic artery in humans. The sizes in terms of the cell diameters have ranged from ~8–10 μm for stem cells (ESCs, HpSCs, BTSCs), to ~12–15 μm for hepatoblasts and committed progenitors, to ~17–18 μm for diploid hepatocytes, found in abundance in neonatal livers, to ~25–30 μm for mature hepatocytes that are dominant in adult livers [2, 3, 6]. Engraftment efficiencies of less than 5% were reported for stem cells when delivered by vascular routes into the livers of primates  or in the livers of humans when injected into the portal vein . Engraftment efficiencies were increased to 20–25% if delivered via the hepatic artery .
In these studies with HA coatings, the danger of thrombi generation has been minimized, because the coating process did not result in large cell clusters. The dimensions of HA-coated hBTSC aggregates (maximum of 3 cells) were within the range of previous studies with uncoated cells (<30 μm), and therefore their administration is hypothesized to be safe.
HA coatings resulted in significant improvements in hBTSC biological properties essential for transplantation and engraftment. Cell viability, colony formation capacity, and PD of HA-coated hBTSCs were better than uncoated cells, as verified in long-term cultures corroborating prior reports of the effects of HA on both normal cells [7, 11, 17, 28], in protecting cells under cryopreservation conditions , and in support of transformed cancer stem cells in vitro and in their survival and proliferation in vivo .
A facet of the ability of the HA coating to facilitate these biologic properties is its ability to maintain critical cell adhesion molecules needed for cell attachment and cell–cell interactions and to prevent them from internalization following cell suspension preparations or with transplantation . We analyzed ITGβ1 (CD29) and ITGβ4 (CD104) integrins that bind, respectively, collagen type III and laminin, CD44, a primary receptor for HA, and, finally, CDH1 (also known as E-cadherin) which allows the formation of cell–cell bonds. A significant enhanced expression of the two integrins, ITGβ1 and ITGβ4, was observed in HA-coated cells and is consistent with the improved in-vitro properties and enhanced engraftment in vivo.
In light of the promising in-vitro findings, we next moved on to in-vivo experiments aimed at evaluating whether HA coating could improve the liver engraftment of hBTSCs. The intrasplenic infusion route was chosen, because it is largely utilized in preclinical studies with different cell types such as hBTSCs. The intrasplenic infusion delivers the cells via the portal vein, a route that routinely yields ~3% engraftment. Our data indicated that HA coating enhanced by 4-fold the engraftment efficiency without detectable spreading of the cells to the kidney and with no increased spread to the lungs over that observed with uncoated cells. In addition, the appearance of signs of differentiation toward mature cells was revealed in engrafted cells. Indeed, using RT-qPCR we demonstrated that, after 30 days, gene expression of human albumin in the mouse liver was markedly enhanced and, consistently, human serum albumin was doubled in mice transplanted with HA-coated vs uncoated hBTSCs. Our method of human albumin detection is highly sensitive, because our primers accurately discriminate between human and mouse albumin, minimizing the possibility of interference. Indeed, we designed primers by considering a specific adenine in the albumin gene sequence that allows a perfect discrimination between the human and murine albumin genes; this adenine avoids the annealing of the primer with the cDNA of murine albumin. Notably, the gene expression and the protein concentration of the albumin in the serum of mice are not directly linked. Different biologic processes involved in the production secretion, metabolism, and excretion of human albumin in the serum of the treated mice could account for this apparent discrepancy. The results concerning albumin secretion are in touch with the IHC observations which showed appearance of signs of differentiation toward mature cells rather than complete differentiation.
In substance, our results indicate that HA coating plays a key role in cell adhesion also in vivo. HA should create a favorable microenvironment allowing a greater number of hBTSCs to engraft within the liver parenchyma, survive, proliferate, and enhance human albumin secretion. When, in previous studies, fibrin was tested, instead of the HA, the same phenomenon was observed . In favor of our proposal is the fact that HA is disposable in GMP grade for clinical use and, primarily, that it is selectively and actively cleared by the liver, an enormous advantage for cell therapies targeting the liver . Therefore, performing the infusion of HA-coated hBTSCs in the portal vein—and even more so via the hepatic artery, if that proves feasible—could permit a greater number of cells to remain confined to the liver without increased extra-hepatic distribution. HA coating could play additional beneficial effects on cell therapy because HA can stimulate the expression of adhesion molecules, thus favoring the proliferation and engraftment of hBTSCs. Previous studies highlighted varied HA trophic effects in different cell systems [12, 13, 20, 21, 38, 42]. HA plays a key role in stabilizing and organizing the ECM by adjusting the adhesion and cell motility, mediating proliferation and differentiation as exemplified in the following examples. The authors demonstrated paracrine interactions between the implanted cells, the host ECM, and endothelial cells, and a proangiogenic effect of degradation of exogenous HA [12, 13, 20, 21, 38, 42].
A current limit of this study is the lack of a proof of performance of HA-coated hBTSCs in experimental models of liver diseases. However, the results obtained and previous observations by Carpino et al.  on the effects of freshly isolated hBTSCs infused in mice subjected to liver fibrosis/cirrhosis induced by carbon tetrachloride, demonstrating an improvement of serum liver biochemistry, guarantee further experiments where hBTSCs will be subjected to HA coating before cell transplantation.
Ectopic cell distribution has been shown to occur following transplants of stem cells into the liver, whether by vascular route or by direct injection, a finding of unknown importance clinically. Ectopic loci of transplanted uncoated cells occurred in all tissues in prior studies. Most studies assumed that the cells did not survive. However, more recent investigations have indicated that the ectopic sites are in most (if not all) tissues where the cells survived for months and could be identified using positron emission tomography . In this study, we have evaluated both the lung and the kidney to test the occurrence of ectopic human cell emboli. Both the lungs and the kidneys appeared invariably normal with respect to histomorphological aspects. By IHC, ectopic distribution occurred only in the lungs and at levels comparable with that found for uncoated cells. This distribution did not occur in the kidneys, a second site known for HA clearance.
An especially advantageous aspect of using HAs to facilitate engraftment is that they are anti-inflammatory and entirely biocompatible. In prior studies with use of HAs for diverse forms of transplantations, they minimize fibrotic reactions and foster vascularization that facilitates engraftment . Finally, no tumoral mass has been observed into the abdomen, liver, spleen, kidney, lungs, or derma at sacrifice, confirming results of prior reports in which the oncogenic potential of transplanted hBTSCs has been evaluated after months and has resulted in a complete absence of tumor formation [24, 25].
We are proposing a simple, rapid, effective, and safe method to improve liver engraftment of transplanted cells for use in the cell therapy of liver diseases. HA-coated hBTSCs can be used immediately in clinical studies because HA is available in GMP conditions.
In summary, coating of hBTSCs with HAs resulted in a 4-fold increase (from ~3% to 11%) in engraftment even when delivered by the portal vein. It will be interesting to see whether HA coating increases the engraftment by an equivalent fold increase if injected into the hepatic artery, where prior findings of uncoated stem cells have indicated an engraftment of 20–25%. Clearly, this simple procedure of coating cells with HAs enables optimized engraftment of cells into the liver when delivered by a vascular route.
Bovine Serum Albumin
Current good manufacturing practice
Epithelial cell adhesion molecule
Embryonic stem cell
Fetal Bovine Serum
Human biliary tree stem cell
Hormonally defined medium
Hepatocyte Paraffin 1
Hepatic stem cell
Induced Pluripotent Stem
Integrin subunit beta
Population Doubling Time
Quantitative reverse-transcription polymerase chain reaction
Severely combined immunodeficient
EG was supported by the research project grant from University “Sapienza” of Rome FIRB grant # RBAP10Z7FS_001 and by PRIN grant # 2009X84L84_001. DA was supported by FIRB grant # RBAP10Z7FS_004 and by PRIN grant # 2009X84L84_002. The study was also supported by Consorzio Interuniversitario Trapianti d’Organo, Rome, Italy and by a sponsored research agreement from Vesta Therapeutics (Bethesda, MD, USA).
Funding for the studies in the USA derived from a sponsored research agreement from Vesta Therapeutics (Bethesda, MD, USA), and from NCI grants (RCA-182322A and CA016086).
Availability of data and materials
LN and GC, co-first authors, were responsible for conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript. DC and OR were responsible for collection and assembly of data, data analysis and interpretation, and final approval of the manuscript. VC was responsible for conception and design, assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript. SDM was responsible for collection and assembly of data, and final approval of the manuscript. FM and PBB were responsible for provision of study material or patients, surgeons involved in the collection of biliary tree discharged during transplantation procedure, and final approval of the manuscript. LR was responsible for conception and design, data analysis and interpretation, revision of the manuscript, and final approval of the manuscript. EG and DA, co-senior authors, were responsible for conception and design, financial support, drafting and revision of the manuscript, and final approval of the manuscript. All authors read and approved the final manuscript.
The authors have declared that no conflict of interest exists. An exception exists for LR, who has an equity position in a biotech company, PhoenixSongs Biologicals, that has a license for the nonclinical use of some of the IP from her laboratory. VC, GC, LR, EG and DA are the inventors of an international patent related to hBTSCs.
Consent for publication
Ethics approval and consent to participate
Human extrahepatic biliary tree, comprising the common hepatic duct, bile duct, cystic duct, gallbladder, and hepato-pancreatic ampulla, were obtained from organ donors from the “Paride Stefanini” Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy. Informed consent to use tissues for research purposes was obtained from our transplant program. All samples derived from adults between the ages of 19 and 73 years. Protocols received the approval of our Institutional Review Board, and processing was compliant with cGMP. The research protocol was reviewed and approved by the Ethic Committee of Umberto I University Hospital, in Rome on 17 June 2010. The reference number of this study is Prot. 541/10. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The informed consent to use tissues discharged during transplantation procedures was obtained from the next of kin of the donor. The privacy rights of human subjects must always be observed.
Studies involving animals
All animal experiments complied with the ARRIVE guidelines and have been carried out in accordance with the EU Directive 2010/63/EU for animal experiments.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Cardinale V, Carpino G, Gentile R, Napoletano C, Rahimi H, Franchitto A, et al. Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis. BMC Gastroenterol. 2014;14:204. (online published).
- Lanzoni G, Oikawa T, Wang YF, Cui CB, Carpino G, Cardinale V, et al. Concise review: Clinical programs of stem cell therapies for liver and pancreas. Stem Cells. 2013;31:2047–60.View ArticlePubMedGoogle Scholar
- Puppi J, Strom SC, Hughes RD, Bansal S, Castell JV, Dagher I, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 2012;21:1–10.View ArticlePubMedGoogle Scholar
- Prestwich GD, Erickson IE, Zarembinski TI, West M, Tew WP. The translational imperative: making cell therapy simple and effective. Acta Biomater. 2012;8:4200–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol. 2015;62:S157–69.View ArticlePubMedGoogle Scholar
- Weber A, Groyer-Picard MT, Franco D, Dagher I. Hepatocyte transplantation in animal models. Liver Transpl. 2009;15:7–14.View ArticlePubMedGoogle Scholar
- Turner RA, Wauthier E, Lozoya O, McClelland R, Bowsher JE, Barbier C, et al. Successful transplantation of human hepatic stem cells with restricted localization to liver using hyaluronan grafts. Hepatology. 2013;57:775–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, Habeeb MA, et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant. 2010;19:409–18.PubMedGoogle Scholar
- Booth C, Soker T, Baptista P, Ross CL, Soker S, Farooq U, et al. Liver bioengineering: current status and future perspectives. World J Gastroenterol. 2012;18:6926–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23:H41–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Lozoya OA, Wauthier E, Turner RA, Barbier C, Prestwich GD, Guilak F, et al. Regulation of hepatic stem/progenitor phenotype by microenvironment stiffness in hydrogel models of the human liver stem cell niche. Biomaterials. 2011;32:7389–402.View ArticlePubMedPubMed CentralGoogle Scholar
- Ni YL, Tang ZR, Cao WX, Lin H, Fan YJ, Guo LK, et al. Tough and elastic hydrogel of hyaluronic acid and chondroitin sulfate as potential cell scaffold materials. Int J Biol Macromol. 2015;74:367–75.View ArticlePubMedGoogle Scholar
- Yan YM, Zuo XS, Wei DY. Concise Review: Emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4:1033–43.View ArticlePubMedPubMed CentralGoogle Scholar
- Harrill JA, Parks BB, Wauthier E, Rowlands JC, Reid LM, Thomas RS. Lineage-dependent effects of aryl hydrocarbon receptor agonists contribute to liver tumorigenesis. Hepatology. 2015;61:548–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Oikawa T, Wauthier E, Dinh TA, Selitsky SR, Reyna-Neyra A, Carpino G, et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nat Commun. 2015;6:8070.View ArticlePubMedPubMed CentralGoogle Scholar
- Turner RA, Mendel G, Wauthier E, Barbier C, Reid LM. Hyaluronan-supplemented buffers preserve adhesion mechanisms facilitating cryopreservation of human hepatic stem/progenitor cells. Cell Transplant. 2012;21:2257–66.View ArticlePubMedGoogle Scholar
- Turner WS, Schmelzer E, McClelland R, Wauthier E, Chen W, Reid LM. Human hepatoblast phenotype maintained by hyaluronan hydrogels. J Biomed Mater Res B Appl Biomater. 2007;82b:156–68.View ArticleGoogle Scholar
- Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci. 1998;3:d604–15.View ArticlePubMedGoogle Scholar
- Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 2007;5:553–67.View ArticlePubMedGoogle Scholar
- Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. J Biol Chem. 2000;275:26967–75.PubMedGoogle Scholar
- Schmidt DS, Klingbeil P, Schnolzer M, Zoller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res. 2004;297:329–47.View ArticlePubMedGoogle Scholar
- Fraser JR, Alcorn D, Laurent TC, Robinson AD, Ryan GB. Uptake of circulating hyaluronic acid by the rat liver. Cellular localization in situ. Cell Tissue Res. 1985;242:505–10.View ArticlePubMedGoogle Scholar
- Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Flisiak R, Swiderska M, et al. Hyaluronic acid concentration in liver diseases. Clin Exp Med. 2016;16(4): 523–8.
- Cardinale V, Wang YF, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54:2159–72.View ArticlePubMedGoogle Scholar
- Carpino G, Cardinale V, Gentile R, Onori P, Semeraro R, Franchitto A, et al. Evidence for multipotent endodermal stem/progenitor cell populations in human gallbladder. J Hepatol. 2014;60:1194–202.View ArticlePubMedGoogle Scholar
- Semeraro R, Cardinale V, Carpino G, Gentile R, Napoli C, Venere R, et al. The fetal liver as cell source for the regenerative medicine of liver and pancreas. Ann Transl Med. 2013;1:13.PubMedPubMed CentralGoogle Scholar
- Riccio M, Carnevale G, Cardinale V, Gibellini L, De Biasi S, Pisciotta A, et al. The Fas/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem/progenitor cells. J Hepatol. 2014;61:1097–105.View ArticlePubMedGoogle Scholar
- Wang Y, Lanzoni G, Carpino G, Cui CB, Dominguez-Bendala J, Wauthier E, et al. Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis. Stem Cells. 2013;31:1966–79.View ArticlePubMedPubMed CentralGoogle Scholar
- Kubota H, Reid LM. Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen. Proc Natl Acad Sci U S A. 2000;97:12132–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med. 2007;204:1973–87.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang YF, Yao HL, Cui CB, Wauthier E, Barbier C, Costello MJ, et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver Fates. Hepatology. 2010;52:1443–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat. 2012;220:186–99.View ArticlePubMedGoogle Scholar
- Furth ME, Wang Y, Cardinale V, Carpino G, Lanzoni G, Cui CB, et al. Stem cell populations giving rise to liver, biliary tree and pancreas. In: Sell S, editor. The Stem Cells Handbook. 2nd ed. New York City: Springer Science Publishers; 2013. p. 283–310.View ArticleGoogle Scholar
- Kajstura J, Rota M, Hall SR, Hosoda T, D’Amario D, Sanada F, et al. Evidence for human lung stem cells. N Engl J Med. 2011;364:1795–806.View ArticlePubMedPubMed CentralGoogle Scholar
- Pisciotta A, Riccio M, Carnevale G, Beretti F, Gibellini L, Maraldi T, et al. Human serum promotes osteogenic differentiation of human dental pulp stem cells in vitro and in vivo. Plos One. 2012;7(11):e50542. (online published).
- Ribaudo R, Gilman M, Kingston RE, Chomczynski P, Sacchi N. Preparation of RNA from tissues and cells. Curr Protoc Neurosci. 2001;Appendix 1:Appendix 1I.
- Dietrich I, Cochet O, Villageois P, Rodrigues CJ. Engraftment of human adipose derived stem cells delivered in a hyaluronic acid preparation in mice. Acta Cir Bras. 2012;27:283–9.View ArticlePubMedGoogle Scholar
- Shu XZ, Ahmad S, Liu YC, Prestwich GD. Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A. 2006;79a:902–12
- de Santana RB, de Santana CM. Human intrabony defect regeneration with rhFGF-2 and hyaluronic acid—a randomized controlled clinical trial. J Clin Periodontol. 2015;42:658–65.View ArticlePubMedGoogle Scholar
- Genovesi A, Barone A, Toti P, Covani U. The efficacy of 0.12% chlorhexidine versus 0.12% chlorhexidine plus hyaluronic acid mouthwash on healing of submerged single implant insertion areas: a short-term randomized controlled clinical trial. Int J Dent Hyg. 2017;15(1):65–72.
- Roberts JJ, Nicodemus GD, Giunta S, Bryant SJ. Incorporation of biomimetic matrix molecules in PEG hydrogels enhances matrix deposition and reduces load-induced loss of chondrocyte-secreted matrix. J Biomed Mater Res A. 2011;97:281–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Kujawa MJ, Carrino DA, Caplan AI. Substrate-bonded hyaluronic-acid exhibits a size-dependent stimulation of chondrogenic differentiation of stage-24 limb mesenchymal cells in culture. Dev Biol. 1986;114:519–28.View ArticlePubMedGoogle Scholar